Novo Nordisk and Eli Lilly initiate legal action against counterfeit GLP-1 drug manufacturers

Novo Nordisk and Eli Lilly are aggressively targeting producers of counterfeit and unauthorized versions of their blockbuster weight-loss drugs, Ozempic and Mounjaro. The proliferation of these illicit products poses significant patient safety risks and threatens the companies' market exclusivity, though the full scale of the black market remains difficult to quantify.